Bukwang Pharmaceutical Co., Ltd.(KR:003000)
â‚©3,800.00-100.00 (-2.56%)
KR:003000
Bukwang Pharmaceutical Co., Ltd. financials statements
â‚©3,800.00
At close:-100.00 (-2.56%)
Want to see KR:003000 full AI Analyst Report?
Bukwang Pharmaceutical Co., Ltd. (003000) Ratios
Bukwang Pharmaceutical Co., Ltd. Ratios
KR:003000's free cash flow for Q3 2026 was ₩-6.76B. For the 2026 fiscal year, KR:003000's free cash flow was decreased by ₩-1.86B and operating cash flow was ₩-4.89B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.59 | 5.76 | 2.61 | 4.90 | 5.95 |
| Quick Ratio | 2.15 | 4.58 | 2.02 | 4.04 | 4.89 |
| Cash Ratio | 0.33 | 2.55 | 1.55 | 1.92 | 2.24 |
| Solvency Ratio | 0.11 | 0.01 | -0.14 | 0.02 | 0.03 |
| Operating Cash Flow Ratio | 0.16 | 0.97 | -0.11 | 0.37 | 0.72 |
| Short-Term Operating Cash Flow Coverage | 0.23 | 263.93 | -48.25 | 0.00 | 0.00 |
| Net Current Asset Value | â‚© 144.25B | â‚© 74.70B | â‚© 59.43B | â‚© 89.66B | â‚© 102.74B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.21 | 0.19 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.24 | 0.33 | 0.35 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.19 | 0.25 | 0.26 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.24 | 0.26 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.47 | 1.53 | 1.90 | 1.52 | 1.47 |
| Debt Service Coverage Ratio | 0.31 | 1.08 | -6.54 | 0.95 | 3.42 |
| Interest Coverage Ratio | 3.63 | 0.25 | -9.85 | -0.13 | 3.99 |
| Debt to Market Cap | 0.21 | 0.25 | 0.18 | 0.00 | 0.00 |
| Interest Debt Per Share | 853.76 | 1255.04 | 1216.20 | 39.31 | 43.33 |
| Net Debt to EBITDA | 2.09 | -1.40 | 2.28 | -17.31 | -7.12 |
| Profitability Margins | |||||
| Gross Profit Margin | 47.69% | 46.44% | 39.74% | 41.61% | 41.51% |
| EBIT Margin | 7.05% | 2.20% | -28.40% | -0.12% | 3.59% |
| EBITDA Margin | 9.79% | 4.76% | -24.99% | 2.56% | 6.25% |
| Operating Profit Margin | 7.05% | 1.01% | -29.78% | -0.12% | 3.08% |
| Pretax Profit Margin | 3.18% | -1.85% | -31.42% | -0.54% | 2.08% |
| Net Profit Margin | 6.26% | -1.65% | -24.88% | -1.30% | -0.50% |
| Continuous Operations Profit Margin | 6.19% | -2.16% | -27.32% | -2.23% | -1.53% |
| Net Income Per EBT | 196.88% | 88.95% | 79.18% | 239.61% | -24.20% |
| EBT Per EBIT | 45.11% | -183.57% | 105.53% | 447.84% | 67.37% |
| Return on Assets (ROA) | 2.50% | -0.71% | -7.30% | -0.62% | -0.23% |
| Return on Equity (ROE) | 3.68% | -1.08% | -13.84% | -0.94% | -0.34% |
| Return on Capital Employed (ROCE) | 3.69% | 0.48% | -11.31% | -0.06% | 1.56% |
| Return on Invested Capital (ROIC) | 3.05% | 0.48% | -9.82% | -0.06% | -1.15% |
| Return on Tangible Assets | 2.53% | -0.72% | -7.48% | -0.63% | -0.23% |
| Earnings Yield | 3.37% | -0.84% | -7.25% | -0.40% | -0.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.59 | 6.52 | 3.28 | 2.17 | 1.91 |
| Payables Turnover | 14.39 | 16.94 | 32.04 | 6.74 | 14.38 |
| Inventory Turnover | 2.01 | 2.06 | 1.34 | 2.89 | 2.72 |
| Fixed Asset Turnover | 1.38 | 1.13 | 1.03 | 1.54 | 1.47 |
| Asset Turnover | 0.40 | 0.43 | 0.29 | 0.48 | 0.46 |
| Working Capital Turnover Ratio | 1.13 | 0.99 | 0.76 | 1.07 | 0.99 |
| Cash Conversion Cycle | 211.50 | 211.80 | 373.40 | 240.43 | 300.11 |
| Days of Sales Outstanding | 55.38 | 55.98 | 111.43 | 168.15 | 191.11 |
| Days of Inventory Outstanding | 181.49 | 177.37 | 273.36 | 126.40 | 134.38 |
| Days of Payables Outstanding | 25.37 | 21.55 | 11.39 | 54.12 | 25.38 |
| Operating Cycle | 236.87 | 233.35 | 384.79 | 294.55 | 325.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 187.33 | 501.96 | -153.50 | 240.47 | 387.45 |
| Free Cash Flow Per Share | 113.03 | 463.80 | -194.65 | 167.57 | 375.92 |
| Dividend Paid and CapEx Coverage Ratio | 1.51 | 13.15 | -3.73 | 1.39 | 3.78 |
| Capital Expenditure Coverage Ratio | 2.52 | 13.15 | -3.73 | 3.30 | 33.60 |
| Operating Cash Flow Coverage Ratio | 0.23 | 0.43 | -0.13 | 17.69 | 17.02 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.21 | -0.08 | 0.09 | 0.15 |
| Free Cash Flow Yield | 2.99% | 10.10% | -3.08% | 1.85% | 2.91% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.90 | -118.94 | -13.80 | -250.60 | -963.47 |
| Price-to-Sales (P/S) Ratio | 1.86 | 1.96 | 3.43 | 3.25 | 4.84 |
| Price-to-Book (P/B) Ratio | 1.09 | 1.29 | 1.91 | 2.36 | 3.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 33.49 | 9.90 | -32.47 | 54.07 | 34.32 |
| Price-to-Operating Cash Flow Ratio | 20.21 | 9.14 | -41.17 | 37.68 | 33.29 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 1.30 | -0.01 | -1.47 | 11.04 |
| Enterprise Value Multiple | 21.10 | 39.80 | -11.45 | 109.63 | 70.35 |
| Enterprise Value | 414.58B | 303.54B | 360.48B | 535.62B | 801.92B |
| EV to EBITDA | 21.10 | 39.80 | -11.45 | 109.63 | 70.35 |
| EV to Sales | 2.07 | 1.90 | 2.86 | 2.81 | 4.39 |
| EV to Free Cash Flow | 37.18 | 9.56 | -27.07 | 46.69 | 31.16 |
| EV to Operating Cash Flow | 22.43 | 8.83 | -34.33 | 32.54 | 30.23 |
| Tangible Book Value Per Share | 3404.24 | 3474.85 | 3277.66 | 3869.06 | 3988.91 |
| Shareholders’ Equity Per Share | 3460.83 | 3559.65 | 3308.40 | 3845.12 | 3938.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.95 | -0.16 | 0.13 | -3.11 | 1.74 |
| Revenue Per Share | 2034.30 | 2338.57 | 1840.92 | 2788.83 | 2665.66 |
| Net Income Per Share | 127.43 | -38.58 | -458.00 | -36.15 | -13.39 |
| Tax Burden | 1.97 | 0.89 | 0.79 | 2.40 | -0.24 |
| Interest Burden | 0.45 | -0.84 | 1.11 | 4.48 | 0.58 |
| Research & Development to Revenue | 0.12 | 0.15 | 0.27 | 0.13 | 0.12 |
| SG&A to Revenue | 0.12 | 0.11 | 0.18 | 0.10 | 0.07 |
| Stock-Based Compensation to Revenue | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.47 | -11.57 | 0.34 | -15.94 | 7.00 |
Currency in KRW

